A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

Trial Profile

A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Dec 2017

At a glance

  • Drugs Axicabtagene ciloleucel (Primary) ; Cyclophosphamide; Fludarabine
  • Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ZUMA-1
  • Sponsors Kite Pharma
  • Most Recent Events

    • 10 Dec 2017 According to a Moffitt Cancer Center media release, results from this trial have been published in The New England Journal of Medicine and were presented at the American Society of Hematology (ASH) Annual Meeting.
    • 04 Dec 2017 According to a Moffitt Cancer Center media release, additional findings from the ZUMA-1 clinical trial will be presented at the American Society of Hematology Annual Meeting 2017.
    • 18 Oct 2017 According to a Dana-Farber Cancer Institute media release, results from this trial presented at the Lugano International Conference on Malignant Lymphoma in June .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top